CERo Therapeutics completes second cohort of phase 1 cancer trial

May 11, 2026 8:15 AM

CERo Therapeutics Holdings Inc. (OTCQB: CERO) completed dosing and the 28-day dose-limiting toxicity assessment period for three patients in the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found